Email this article Immunophenotypic characterization of acute megakaryoblastic leukaemia in children
- Authors: Alexenko M.Y.1, Illarionova O.I.1, Verzhbitskaya N.Y.2,3, Zerkalenkova E.A.1, Novikova I.A.4, Panferova A.V.1, Fechina L.G.2,3, Tsaur G.A.2,3, Olshanskaya Y.V.1, Popov A.M.1
-
Affiliations:
- Dmitriy Rogachev National Medical Research Center of Pediatric Hematology , Oncology, Immunology Ministry of Healthcare of Russian Federation
- Regional Children Clinical Hospital № 1
- Research Institute of Medical Cell Technologies
- Rostov Institute of Oncology
- Issue: Vol 18, No 3 (2019)
- Pages: 35-40
- Section: ORIGINAL ARTICLES
- Submitted: 12.09.2019
- Accepted: 12.09.2019
- Published: 12.09.2019
- URL: https://hemoncim.com/jour/article/view/258
- DOI: https://doi.org/10.24287/1726-1708-2019-18-3-35-40
- ID: 258
Cite item
Full Text
Abstract
Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia, in which the bone marrow produce increased numbers of immature abnormal megakaryoblasts. AMKL is rare both in children and adults, but is the most frequent subtype of acute myeloid leukemia (AML) in children with Down syndrome. Morphological diagnosis of this disease could be complicated, thus flow cytometry plays a crucial role in the diagnostics of AMKL. The aim of the present study was to investigate the immunophenotypic characteristics of AMKL in children. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The study group included 103 patients with AMKL. Antigen expression profile was assessed by multicolor flow cytometry. We identified three groups of patients according to different levels of CD45 expression, and in majority of patients (74%) high level of CD45 expression was detected. Significant immunophenotypic differences between these groups were found. In 56% of patients trisomy of 21 chromosome was detected. Among these patients, 86% belonged to group of high CD45 expression. Moreover, children with trisomy 21 represented the majority in the group with high level of CD45 expression (64%). Also, there were found several significant differences between patients with and without trisomy 21 within the group of high CD45 expression. This study demonstrated the wide immunophenotypic heterogeneity of AMKL. In general, the revealed diversity obviously reflects the biological heterogeneity of this AML subtype.
Keywords
About the authors
M. Yu. Alexenko
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation
ORCID iD: 0000-0002-2521-5353
Moscow Russian Federation
O. I. Illarionova
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation
ORCID iD: 0000-0003-2685-674X
Moscow Russian Federation
N/ Yu. Verzhbitskaya
Regional Children Clinical Hospital № 1;Research Institute of Medical Cell Technologies
ORCID iD: 0000-0001-9329-1828
Ekaterinburg Russian Federation
E. A. Zerkalenkova
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation
ORCID iD: 0000-0001-9634-5828
Moscow Russian Federation
I. A. Novikova
Rostov Institute of Oncology
ORCID iD: 0000-0001-6689-5861
Rostov-on-Don Russian Federation
A. V. Panferova
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation
ORCID iD: 0000-0002-8580-3499
Moscow Russian Federation
L. G. Fechina
Regional Children Clinical Hospital № 1;Research Institute of Medical Cell Technologies
ORCID iD: 0000-0002-1885-3912
Ekaterinburg Russian Federation
G. A. Tsaur
Regional Children Clinical Hospital № 1;Research Institute of Medical Cell Technologies
ORCID iD: 0000-0002-9881-6221
Ekaterinburg Russian Federation
Yu. V. Olshanskaya
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation
ORCID iD: 0000-0002-2352-7716
Moscow Russian Federation
A. M. Popov
Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation
Author for correspondence.
Email: uralcytometry@gmail.com
ORCID iD: 0000-0002-0889-6986
Alexander M. Popov, MD, PhD, Head of Hemoblastosis immunophenotyping laboratory of the Department of pediatric oncological surgery
117997, Moscow, Samory Mashela st., 1
Russian FederationReferences
Supplementary files
